Hausberg Martin, Lang Detlef, Levers Andrea, Suwelack Barbara, Kisters Klaus, Tokmak Faruk, Barenbrock Michael, Kosch Markus
Department of Internal Medicine D, University of Muenster, Muenster, Germany.
J Hypertens. 2006 May;24(5):957-64. doi: 10.1097/01.hjh.0000222767.15100.e4.
It has been suggested that the increase in blood pressure observed in transplant patients treated with cyclosporine is mediated by cyclosporine-induced sympathoexcitation. However, the chronic effects of cyclosporine on sympathetic outflow in renal transplant patients have not been investigated. Therefore we studied sympathetic nerve activity and blood pressure before and 6 months after the withdrawal of cyclosporine in renal transplant patients.
Twenty-four renal transplant patients with histologically confirmed chronic allograft nephropathy (age 48 +/- 3 years, 60 +/- 10 months after transplantation) were included in the prospective study and randomly assigned to either withdrawal (n = 12) or continuation (n = 12) of cyclosporine. Both groups received mycophenolate mofetil and prednisolone as additional immunosuppressants. At entry and 6 months later blood pressure, muscle sympathetic nerve activity (MSNA), and plasma norepinephrine were measured. To assess the potential influence of the diseased native kidneys, three renal transplant patients who had their native kidneys removed were studied before and after cyclosporine withdrawal.
Mean arterial pressure decreased significantly in the cyclosporine-withdrawal group (95 +/- 4 versus 105 +/- 4 mmHg 6 versus 0 months, P < 0.05) but not in the cyclosporine-continuation group (103 +/- 3 versus 105 +/- 4 mmHg, NS). However, plasma norepinephrine and MSNA did not change significantly in either group (MSNA 43 +/- 4 versus 44 +/- 3 and 38 +/- 5 versus 39 +/- 4 bursts/min in the cyclosporine-withdrawal and cyclosporine-continuation groups, NS). Graft function remained stable in both groups and in transplant patients who had their native kidneys removed MSNA did not decrease after cyclosporine withdrawal.
The withdrawal of cyclosporine in renal transplant patients, receiving relatively low doses of cyclosporine, resulted in a substantial decrease in blood pressure. However, MSNA and norepinephrine did not change. This suggests that cyclosporine treatment does not cause chronic sympathetic activation that could explain the cyclosporine-induced blood pressure elevation in renal transplant patients.
有研究表明,接受环孢素治疗的移植患者血压升高是由环孢素诱导的交感神经兴奋介导的。然而,环孢素对肾移植患者交感神经输出的慢性影响尚未得到研究。因此,我们研究了肾移植患者停用环孢素前及停药6个月后的交感神经活动和血压。
24例经组织学证实为慢性移植肾肾病的肾移植患者(年龄48±3岁,移植后60±10个月)纳入前瞻性研究,并随机分为停用环孢素组(n = 12)和继续使用环孢素组(n = 12)。两组均接受霉酚酸酯和泼尼松龙作为额外的免疫抑制剂。在入组时和6个月后测量血压、肌肉交感神经活动(MSNA)和血浆去甲肾上腺素。为评估患病的自体肾的潜在影响,对3例切除了自体肾的肾移植患者在停用环孢素前后进行了研究。
环孢素停药组平均动脉压显著降低(6个月时95±4 mmHg,0个月时105±4 mmHg,P < 0.05),而继续使用环孢素组未降低(103±3 mmHg对105±4 mmHg,无显著性差异)。然而,两组血浆去甲肾上腺素和MSNA均无显著变化(环孢素停药组和继续使用环孢素组的MSNA分别为43±4次/分钟对44±3次/分钟,38±5次/分钟对39±4次/分钟,无显著性差异)。两组移植肾功能均保持稳定,切除了自体肾的移植患者停用环孢素后MSNA未降低。
对于接受相对低剂量环孢素治疗的肾移植患者,停用环孢素导致血压大幅下降。然而,MSNA和去甲肾上腺素并未改变。这表明环孢素治疗不会引起慢性交感神经激活,而这可能解释肾移植患者中环孢素诱导的血压升高。